Skip to main content
. 2011 Mar 8;7(1):102–111. doi: 10.5114/aoms.2011.20612

Table II.

Changes in ADAS-cog Scores, CDR-SB Scores (ITT population) and hippocampus volume (MRI–ITT population)

Outcome/group Baseline Change from Baseline/Week
13 26 39 52 65 78
n Mean SD n LS Mean 95% Cl n LS Mean 95% Cl n LS Mean 95% Cl n LS Mean 95% Cl n LS Mean 95% Cl n LS Mean 95% Cl
ADAS-cog
 Placebo BID 331 22.2 8.3 326 0.8 0.2-1.4 318 2.2 1.5-2.9 292 3.1 2.4-3.8 284 4.8 4.0-5.7 268 5.9 5.0-6.9 265 7.5 6.5-8.5
 100 mg BID 325 22.1 8.6 322 1.1 0.6-1.7 300 1.2 0.7-1.8 282 2.7 2.1-3.3 279 3.8 3.2-4.5 262 5.3 4.5-6.0 258 6.8 5.9-7.7
 150 mg BID 318 21.7 8.3 316 0.8 0.2-1.4 293 1.7 1.1-2.3 281 2.9 2.2-3.6 267 4.1 3.3-4.9 257 5.7 4.7-6.6 252 7.5 6.4-8.6
CDR-SB
 Placebo BID 336 5.8 2.8 335 0.2 0.1-0.4 322 0.7 0.5-0.9 295 1.2 1.0-1.4 287 1.8 1.6-2.1 270 2.2 1.9-2.5 266 2.6 2.3-3.0
 100 mg BID 327 5.7 2.6 326 0.4 0.2-0.5 301 0.7 0.5-0.9 282 1.1 0.9-1.3 275 1.6 1.4-1.9 260 1.9 1.7-2.2 258 2.4 2.1-2.8
 150 mg BID 320 5.7 2.5 316 0.2 0.1-0.4 294 0.6 0.4-0.8 282 1.0 0.8-1.3 267 1.5 1.3-1.8 254 2.0 1.7-2.3 253 2.6 2.2-3.0
HV [mm3]
 Placebo BID 109 3294.4 723.4 109 -202.2 237.0
 100 mg BID 103 3278.9 741.2 103 -210.6 237.5
 150 mg BID 100 3405.9 702.6 100 -259.7 235.0

Higher scores on ADAS-cog and CDR-SB indicate greater impairment and LS mean changes from Baseline > 0 indicate deterioration. Hippocampus volume (HV) change < 0 indicates atrophy

HHS Vulnerability Disclosure